

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Not for Submission under 37 CFR 1.99)*

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

**U.S. PATENTS**

Examiner Initial*	Cite No.	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages Columns Lines where Relevant Passages or Relevant Figures Appear
	1	5585103		1996-12-17	Raychaundhuri et al.	
	2	5597895		1997-01-28	Gaynor et al.	
	3	5616559		1997-04-01	Androphy et al.	
	4	5652122		1997-07-29	Frankel et al.	
	5	5656599		1997-08-12	Androphy et al.	
	6	5670617		1997-09-23	Frankel et al.	
	7	5674980		1997-10-17	Frankel et al.	
	8	5686264		1997-11-11	Gaynor et al.	
	9	5747641		1998-05-05	Frankel et al.	
	10	5804604		1998-09-08	Frankel et al.	
	11	5889175		1999-03-30	Mehtali et al.	
	12	5891994		1999-04-06	Goldstein	
	13	5942401		1999-08-24	van Baalen et al.	
	14	5981258		1999-11-09	Mehtali et al.	
	15	6024965		2000-02-15	van Baalen et al.	
	16	6132721		2000-10-17	Zagury et al.	
	17	6193981		2001-02-27	Goldstein	
	18	6194388		2001-02-27	Krieg et al.	
	19	6200575		2001-03-13	Zagury et al.	
	20	6207646		2001-03-27	Krieg et al.	
	21	6228369		2001-05-08	Mehtali et al.	
	22	6239116		2001-05-29	Krieg et al.	
	23	6270769		2001-08-07	Raychaundhuri et al.	
	24	6284252		2001-09-04	Mehtali et al.	
	25	6316003		2001-11-13	Frankel et al.	
	26	6319666		2001-11-20	van Baalen et al.	
	27	6339068		2002-01-15	Krieg et al.	
	28	6406705		2002-06-18	Davis et al.	
	29	6420141		2002-07-16	Zagury et al.	
	30	6797491		2002-09-28	Neefe et al.	
	31	6495347		2002-12-17	Siegel et al.	
	32	6497880		2002-12-24	Wisniewski	
	33	6524825		2003-02-25	Mizzen et al.	
	34	6524582		2003-02-25	Goldstein	
	35	6525179		2003-02-25	Goldstein	
	36	6593292		2003-07-15	Rothbard et al.	
	37	6657055		2003-12-02	Siegel et al.	
	38	6667151		2003-12-23	Cohen	
	39	6686333		2004-02-03	Kashanchi et al.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for Submission under 37 CFR 1.99)

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No.	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages Columns Lines where Relevant Passages or Relevant Figures Appear
	1	20020091073		2002-07-11	Finkel et al.	
	2	20020193330		2002-12-19		
	3	20020197269		2002-12-26	Lingnau et al.	
	4	20030003160		2003-01-02	Zagury et al.	
	5	20030091599		2003-05-15	Davis et al.	
	6	20030099663		2003-05-29	Fleitmann et al.	
	7	20030099664		2003-05-29	Wisniewski	
	8	20030148456		2003-08-07	Mizzen et al.	
	9	20030158134		2003-08-21	Voss	
	10	20030162719		2003-08-28	Rothbard et al.	
	11	20030166832		2003-09-04	Goldstein	
	12	20030180326		2003-09-25	Goldstein	
	13	20030224010		2003-12-04	Davis et al.	
	14	20030232074		2003-12-28	Lipford et al.	
	15	20040001852		2004-01-01	Zagury et al.	
	16	20040005330		2004-01-08	Rappaport et al.	
	17	20040009949		2004-01-15	Krieg	
	18	20040028652		2004-02-12	Wang et al.	
	19	20040034209		2004-02-19	Ho et al.	
	20	20040054137		2004-03-18	Thomson et al.	
	21					
	22					
	23					
	24					

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for Submission under 37 CFR 1.99)

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No.	Foreign Document Number	Country Code	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of Cited Document	Pages Columns Lines Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		0 673 948	EP		1998-11-11	Dade Behring		
		0 814 834	EP		2000-09-13	Neovacs		
		1 279 404	EP		2003-01-29	Instituto Superiore di Sanita		
		91/15224	WO		1991-10-17	SmithKline Beecham		
		91/18454	WO		1991-11-28	Centre National de la Recherche Scientifique		
		94/15634	WO		1994-07-21	Rath		
		95/31999	WO		1995-11-30	Immunology Research Institute		
		96/27389	WO		1996-09-12	Neovacs		
		98/14589	WO		1998-04-09	Government of the United States		
		98/17309	WO		1998-04-30	Erasm University		
		98/43669	WO		1998-10-08	Thomas Jefferson Univ.		
		98/46083	WO		1998-10-22	Reagents of the University of Calif.		
		99/02185	WO		1999-01-21	Thymon LLC		
		99/16884	WO		1999-04-08	SmithKline Beecham		
		99/27958	WO		1999-06-10	Instituto Superiore di Sanita		
		99/33346	WO		1999-07-08	Zagury et al.		
		99/33872	WO		1999-07-08	Neovacs		
		00/03732	WO		2000-01-27	Vacs International		
		00/78334	WO		2000-12-28	U. Maryland Biotech Inst. Inst. Mol. Cell. Biol.		
		00/78969	WO		2000-12-28	Government of the United States		
		01/00232	WO		2001-01-04	SmithKline Beecham		
		01/24822	WO		2001-04-12	Cistem Biotech.		
		01/43771	WO		2001-06-21	Neovacs		
		01/78775	WO		2001-10-25	Wisconsin Alumni Res. Foundation		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for Submission under 37 CFR 1.99)

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

## **NONPATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate) title of the item (book magazine journal serial symposium catalog etc.) date page(s) volumeissue number(s) publisher city and/or country where published.	T <sup>5</sup>
		AGWALE SM et al. A Tat subunit vaccine confers protective immunity against the immunomodulating activity of the human immunodeficiency vir type1 Tat protein in mice PNAS 99:1003710041 2002	
		ARLEN PM. et al. Strategies for the Development of PSAbased vaccines for the treatment of advanced prostate cancer Expert Rev. Vaccines Vol. 2 No. 4 pp. 483493 2003	
		BADLEY AD. et al. Upregulation of Fas Ligand Expression by Human Immunodeficiency Vir in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes J Virol 70:199206 January 1996	
		BADLEY AD. et al. Macrophagedependent Apoptosis of CD4+ T Lymphocytes from HIVinfected Individuals is Mediated by FasL and Tumor Necrosis Factor J. Exp. Med. Vol. 185 No. 1 pp. 5564 January 6 1997	
		BAGHIAN, A. et al., "Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunization with herpes simplex virus type-1 genes specifying glycoproteins gB and gD", Journal of Medical Microbiology, Vol. 51, No. 4, 2002, pgs. 350-357	
		BANCHEREAU J et al. Dendritic cells as vectors for therapy Cell 106:2714 2001	
		BAYER P et al. Structural Studies of HIV1 Tat Protein J. Mol. Biol. Vol. 247 pp. 529535 1995	
		BEISSERT S. et al. IL10 Inhibits Tumor Antigen Presentation by Epidermal AntigenPresenting Cells The Journal of Immunology Vol. 154 pp. 12801286 1995	
		BUANEC HL et al. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuo Tat Toxoid Biomedicine and Pharmacotherapy Vo. 52 No. 10 pp. 431435 1998	
		BOYKINS, R.A., et al., "Immunization with a noval HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice", Peptides, 2000, Vol. 21, , pp. 1829-1847	
		CAFARO A. et al. Control of SHIV89.6Pinfection of cynomolg monkeys by HIV1 Tat protein vaccine Nature Medicine Vol. 5 No. 6 pp. 643650 June 1999	
		CAPUTO A. et al. Immunization with low doses of HIV1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat Vaccine Vol. 21 pp. 11031111 2003	
		CASELLI E. et al. DNA immunization with HIV1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wildtype Tat. J Immunol 162:56318 1999.	
		CHEADLE, C., et al., "Identification of a Src SH3 Domain Binding Motif by Screening a Random Phage Display Library", The Journal of Biological Chemistry", 1994, Vol. 269, No. 39, ppgs. 24034-24039	
		CHENCINER et al. Enhancement of humoral immunity to SIVenv following simultaneo inoculation of mice by three recombinant adenovires encoding SIVenvpoliovir chimeras Tat and Rev. AIDS Res Hum Retrovires 13:8016 1997.	
		CHO H. et al. In vitro induction of carcioembryonic antigen (CEA)specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenovires Vaccine Vol. 22 pp. 224236 2003	
		CNN Interactive New HIV Vaccine Concept May Extend Hope to Those Already Infected <a href="http://cnn.com/HEALTH/aids990829/aids.vaccine">http://cnn.com/HEALTH/aids990829/aids.vaccine</a> . pp 13 Augt 1999	
		COHEN SS et al. Pronounced acute immunosuppression in vivo mediated by HIV1 Tat challenge Proc Natl Acad Sci A 96:1084247 1999	
		DALYOTHERMAN N et al. Reversal of CD8+ T cell ignorance and induction of antitumor immunity by peptidepulsed APC J Immunol 165:67317 2000	
		DURRANT LG et al. Cancer vaccines entering Phase III clinical trials Expert Opinion Emerging Drugs Vol. 8 No. 2 pp. 489500 2003	
		ELBASHIR SM et al. RNA Interference is mediated by 21 and 22nucleotide RNAs. Genes Devel 15:188200 2001	
		EMBURY, J., et al., "Proteins Linked to a Protein Transduction Domain Efficiently Transduce Pancreatic Islets", Diabetes, 2001, Vol. 50, pp. 1706-1713	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for Submission under 37 CFR 1.99)

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

## **NONPATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate) title of the item (book magazine journal serial symposium catalog etc.) date page(s) volumeissue number(s) publisher city and/or country where published.	T <sup>5</sup>
		ENSOLI, B., et al., "HIV-1 Tat vaccines, Virus Research", 2002 Vol. 82, pp.91-101	
		FANALESBELASIO E et al. Native HIV1 Tat protein targets monocytederived dendritic cells and enhances their maturation function and antigenspecific T cell responses J Immunol 168:197206 2002	
		FANALESBELASIO E. et al. HIV1 TatBased Vaccines: From Basic Science to Clinical Trials DNA & Cell Biology Vol. 21 No. 9 pp. 599610 2002	
		FAWELL, S., et al., "Tat-mediated delivery of heterologous proteins into cells, Proc. Natl. Acad. Sci., 1994, Vol. 91, pp. 664-668	
		FISHER GH. et al. Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome Cell Vol. 81 pp. 935946 June 16 1995	
		FOLLEN M et al. Cervical Cancer Chemoprevention Vaccines and Surrogate Endpoint Biomarkers American Cancer Society Cancer Supplement Vol. 98 No. 9 pp. 20442051 November 1 2003	
		FRANKEL AD and Pabo CO Cellular uptake of the Tat protein from Human Immunodeficiency Vir Cell 55:118993 1988	
		FRANKEL AD et al. Activity of synthetic peptides from the TAT protein of human immunodeficiency vir type 1 Proc. Natl. Acad. Sci. Vol. 86 pp. 73977401 October 1989	
		FRIEDMAN AD et al. Expression of a truncated viral transactivator selectively impedes lytic infection by its cognate vir Nature Vol. 335 pp. 452454 September 29 1988	
		GALLO RC. Tat as one key HIVinduced immune pathogenesis and Tat toxoid as an important component of a vaccine Proc. Natl. Acad. Sci. A Vol. 96 pp. 83248326 July 1999	
		GARCIAHERNANDEZ ML et al. Interleukin10 promotes B16melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation Immunology Vol. 105 pp. 231243 2002	
		GIANNOULI C. et al. Fion of a Tumourassociated Antigen to HIV1 Tat Improves Proteinbased Immunotherapy of Cancer Anticancer Research Vol. 23 pp. 35233532 2003	
		GOLDSTEIN G. HIV1 Tat protein as a potential AIDS vaccine Nature Medicine Vol. 1 No. 9 pp. 960964 September 1996	
		GREEN M et al. Mutational Analysis of HIV1 Tat Minimal Domain Peptides: Identification of TransDominant Mutants that Suppress HIVLTRDriven Gene Expression Cell Vol. 58 pp. 215223 July 14 1989	
		GRINGERI A. et al. Safety and Immunogenicity of HIV1 Tat Toxoid in Immunocompromised HIV1Infected Patients Journal of Human Virology Vol. 1 No. 4 pp. 293298 MayJune 1998	
		GRINGERI A. et al. Tat Toxoid as a Component of a Preventive Vaccine in Seronegative Subjects Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Vol. 20 No. 4 pp. 371375 April 1 1999	
		HERNANDO JJ et al. Dendritic Cellbased Vaccines in Breast and Gynaecologic Cancer Anticancer Res. 23:42934304 2003.	
		HSIEH CL et al. TumorInduced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by CytokineSecreting Tumor Vaccine Human Gene Therapy Vol. 11 pp. 681692 March 20 2000	
		ISHIGAMI S. et al. Tumorassociated Macrophage (TAM) Infiltration in Gastric Cancer Anticancer Research Vol. 23 pp. 40794084 2003	
		JAGER D. et al. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning <a href="http://www.springerlink.com/mediagmgkwgmxxeebf3wn9h2m">http://www.springerlink.com/mediagmgkwgmxxeebf3wn9h2m</a> ContributinsX39FX39 pp 19 2004	
		JASINSKA J. et al. Inhibition of Tumor Cell Growth by Antibodies Induced After Vaccination with Peptides Derived From the Extracellular Domain of Her2NEU Int. J. Cancer Vol. 107 pp. 976983 2003	
		JIANG S. et al. Fas Mediates Apoptosis and OxidantInduced Cell Death in Cultured hRPE Cells Invest Ophthalmol Vis Sci. Vol. 41 No. 3 pp. 645655 2000	
		KANAZAWA M. et al. Effect of DC Therapy Combined with Chemotherapy in Advanced Cancer Cases Jpn J. Cancer Chemother Vol. 30 No. 11 pp. 16551660 October 2003	

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for Submission under 37 CFR 1.99)

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

## **NONPATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate) title of the item (book magazine journal serial symposium catalog etc.) date page(s) volumeissue number(s) publisher city and/or country where published.	T <sup>5</sup>
		KJAERGAARD J. et al. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine Cellular Immunology Vol. 225 pp. 6574 2003	
		KUPPWAMY M. et al. Multiple functional domains of Tat the transactivator of HIV1 defined by mutational analysis Nucleic Acids Research Vol. 17 No. 9 pp. 35513561 1989	
		LEONARD NJ et al. Periodate Oxidation of Sulfides to Sulfoxides. Scope of the Reaction The Journal of Organic Chemistry Vol. 27 No. 1 pp. 282284 January 1962	
		LEPPLEWIENHUES A. et al. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids PNAS Vol. 96 No. 24 pp. 1379513800 November 23 1999	
		LEWIS SN Peracid and Peroxidase Oxidation. In: Oxidation: Techniques and Applications in Organic Synthesis Volume 1 R.L. Augtine ed. Marcel Dekker Inc. New York pp. 244248 1969	
		LI CJ et al. Tat protein induces selfperpetuating permissivity for productive HIV1 infection Proc. Natl. Acad. Sci A Vol. 94 pp. 81168120 July 1997	
		LI CJ. et al. Induction of Apoptosis in Uninfected Lymphocytes by HIV1 Tat Protein Science Vol. 268 pp. 429431 April 21 1995	
		LIN EY et al. The Macrophage Growth Factor CSF1 in Mammary Gland Development and Tumor Progression Journal of Mammary Gland Biology and Neoplasia Vol. 7 No. 2 pp. 147162 April 2002	
		LIU KJ et al. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligandtransfected tumor cells resulted in efficient activation of specific CD8+ T cells Cancer Gene Therapy Vol. 11 pp. 135147 2004	
		MARTIN MJ et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 11:22832 2005	
		MEDINA F. et al. Regulatory role of CD95 ligation on human B Cells induced in vivo capable of spontaneous and highrate Ig secretion Eur. J. Immunol. Vol. 27 pp. 700706 1997	
		MOY P et al. Tatmediated protein delivery can facilitate MHC class I presentation of antigens Mol Biotechnol 6:10513 1996	
		NAGATA S. Apoptosis by Death Factor Cell Vol. 88 pp. 355365 February 7 1997	
		NOURISHIRAZI M. et al. Dendritic cell based tumor vaccines Immunology Letters Vol. 74 pp. 510 2000	
		NOVAK N et al. Engagement of FcεRI on human monocytes induces the production of IL10 and prevents their differentiation in dendritic cells J Immunol 167:797804 2001	
		PAILLARD F. Immunosuppression Mediated by Tumor Cells: A Challenge for Immunotherapeutic Approaches Human Gene Therapy Vol. 11 pp. 657658 March 20 2000	
		PETER ME et al. Resistance of cultured peripheral T cells towards activationinduced cell death involves a lack of recruitment of FLICE (machCASPASE 8) to the CD95 deathinducing signaling complex Eur. J. Immunol. Vol. 27 pp. 12071212 1997	
		PHAN CQ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sc. A 100:83727 2003	
		RANA TM et al. Biochemical and Functional Interactions between HIV1 Tat Protein and TAR RNA Archives of Biochemistry and Biophysics Vol. 365 No. 2 pp. 175185 May 15 1999	
		REINHOLD D. et al., "HIV-1 Tat: Immunosuppression via TGF-beta1 Induction", Immunology Today, Elsevier Publications, Vol. 20, No. 8, 1999, pg. 384	
		SCHLUESENER HJ Protection against generalized autoimmunity of the nervous system (GANS) a novel animal model with combined features of EAE EAN and EAU by a recombinant HIV1 Tat3772 peptidebased multiple T cell epitope vaccine. FEMS Immunol Med Microbiol 17:17986 1997.	
		SCHLUESENER HJ Protection against experimental nervous system autoimmune diseases by a human immunodeficiency virus1 Tat peptidebased polyvalent vaccine. J Neurosci Res. 46:25862 1996.	
		SCHWARZE SR et al. In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285:156972 1999	
		SMALL EJ et al. Immunotherapy of HormoneRefractory Prostate Cancer with AntigenLoaded Dendritic Cells Journal of Clinical Oncology Vol. 18 No. 23 pp. 38943903 December 1 2000	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Not for Submission under 37 CFR 1.99)

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate) title of the item (book magazine journal serial symposium catalog etc.) date page(s) volume issue number(s) publisher city and/or country where published.	T <sup>5</sup>
		STEBBING J et al. Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor Blood 102:180814 2003	
		STOHL W. et al. Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell Death Cellular Immunology Vol. 203 pp. 111 2000	
		STOHL W et al. Superantigen-Driven CD8 <sup>+</sup> T Cell-Mediated Downregulation: CD95 (Fas)-Dependent Downregulation of Human Ig Responses Despite CD95-Independent Killing of Activated B Cells The Journal of Immunology Vol. 161 pp. 3292-3298 1998	
		SUZUE K et al. Heat shock proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway Immunol 94:1314651 1997	
		TASCA, S., et al., "Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis" AIDS, Vol. 17, No. 16, 2003, pgs. 2291-2298	
		TOSI G et al. Highly stable oligomerization forms of HIV1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV1 LTR Eur J Immunol 30:11206 2000	
		TURTLE CJ et al. Dendritic Cells in Tumor Immunology and Immunotherapy Current Drug Targets Vol. 5 No. 1 pp. 1739 2004	
		TZACHANIS D et al. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages which suppress T cell responses Blood 99:146573 2002	
		VISCIDI RP et al. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV1 Science 146:16068 1989	
		VISSCHER DW et al. Clinicopathologic Analysis of Macrophage Infiltrates in Breast Carcinoma Path. Res. Pract (Suppl). Vol. 191 pp. 1133-1139 1995	
		VOCERO-AKBANI, A.M. et al., "Killing HIV-Infected Cells by Transduction with an HIV Protease-Activated Caspase-3 Protein", Nature Medicine, Vol. 5, No. 1, pp. 29-33, 1999	
		VON BERNSTORFF W. et al. Systemic and Local Immunosuppression in Pancreatic Cancer Patients Clinical Cancer Research Vol. 7 pp. 925s-932s March 2001	
		WACHSMAN W. et al. HTLV x Gene Mutants Exhibit Novel Transcriptional Regulatory Phenotypes Science Vol. 235 pp. 674-677 February 6 1987	
		WESTENDORP MO. et al. Sensitization of T Cells to CD95-mediated apoptosis by HIV1 Tat and gp120 Nature Vol. 375 pp. 497-500 June 8 1995	
		ZHANG H et al. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells J Immunol 162:142330 1999.	

**EXAMINER SIGNATURE**

Examiner Signature	/Stuart Snyder/	Date Considered	12/03/2010
--------------------	-----------------	-----------------	------------

\*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>See Kind Codes of PTO Patent Documents at [www.PTO.GOV](http://www.PTO.GOV) or MPEP 901.04. <sup>2</sup>Enter office that issued the document by the two-letter code (WIPO Standard ST.3). <sup>3</sup>For Japanese patent documents the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Not for Submission under 37 CFR 1.99)*

Application Number	10/598,978
Filing Date	09/15/2006
First Named Inventor	David I. Cohen
Art Unit	1648
Examiner Name	Snyder, Stuart

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97 (e)(1).

**OR**

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the certification after making reasonable inquiry no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97 (e)(2).

- ☒ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33 10.1. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michelle S. Glasky/	Date(YYYYMMDD)	2008-11-3
NamePrint	Michelle S. Glasky, Ph.D.	Registration Number	54124

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete including gathering preparing and submitting the completed application form to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer U.S. Patent and Trademark Office U.S. Department of Commerce P.O. Box 1450 Alexandria VA 223131450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. **SEND TO: Commissioner for Patents P.O. Box 1450 Alexandria VA 223131450.**